DE19906978B4 - Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit - Google Patents
Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit Download PDFInfo
- Publication number
- DE19906978B4 DE19906978B4 DE19906978A DE19906978A DE19906978B4 DE 19906978 B4 DE19906978 B4 DE 19906978B4 DE 19906978 A DE19906978 A DE 19906978A DE 19906978 A DE19906978 A DE 19906978A DE 19906978 B4 DE19906978 B4 DE 19906978B4
- Authority
- DE
- Germany
- Prior art keywords
- deoxypeganine
- treatment
- drug
- drug addiction
- drug dependence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 206010013663 drug dependence Diseases 0.000 title claims abstract description 18
- 208000011117 substance-related disease Diseases 0.000 title claims abstract description 18
- VARHXCYGZKSOOO-UHFFFAOYSA-N Deoxyvasicinone Natural products C1=CC=C2C(=O)N(CCC3)C3=NC2=C1 VARHXCYGZKSOOO-UHFFFAOYSA-N 0.000 title claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 11
- 238000007911 parenteral administration Methods 0.000 abstract description 3
- 238000013270 controlled release Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- -1 Flow improver Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 240000005523 Peganum harmala Species 0.000 description 1
- 235000005126 Peganum harmala Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906978A DE19906978B4 (de) | 1999-02-19 | 1999-02-19 | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
| AU32788/00A AU3278800A (en) | 1999-02-19 | 2000-02-08 | Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence |
| JP2000599374A JP2002537246A (ja) | 1999-02-19 | 2000-02-08 | 薬物依存症の治療のためのデオキシペガニン含有医薬組成物 |
| KR1020017010490A KR20010102239A (ko) | 1999-02-19 | 2000-02-08 | 약물 의존증 치료를 위한 데옥시페가닌을 포함하는 약학조성물 |
| EP00910649A EP1152763B1 (de) | 1999-02-19 | 2000-02-08 | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit |
| AT00910649T ATE228843T1 (de) | 1999-02-19 | 2000-02-08 | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit |
| US09/889,648 US6599511B1 (en) | 1999-02-19 | 2000-02-08 | Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence |
| DK00910649T DK1152763T3 (da) | 1999-02-19 | 2000-02-08 | Anvendelse af desozypeganin til behandling af stofafhængighed |
| DE50000864T DE50000864D1 (de) | 1999-02-19 | 2000-02-08 | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit |
| ES00910649T ES2188513T3 (es) | 1999-02-19 | 2000-02-08 | Utilizacion de desoxipeganina para el tratamiento de la drogodependencia. |
| PCT/EP2000/000974 WO2000048582A2 (de) | 1999-02-19 | 2000-02-08 | Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der drogenabhängigkeit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906978A DE19906978B4 (de) | 1999-02-19 | 1999-02-19 | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19906978A1 DE19906978A1 (de) | 2000-08-24 |
| DE19906978B4 true DE19906978B4 (de) | 2004-07-08 |
Family
ID=7898024
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19906978A Expired - Fee Related DE19906978B4 (de) | 1999-02-19 | 1999-02-19 | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
| DE50000864T Expired - Fee Related DE50000864D1 (de) | 1999-02-19 | 2000-02-08 | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50000864T Expired - Fee Related DE50000864D1 (de) | 1999-02-19 | 2000-02-08 | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6599511B1 (enExample) |
| EP (1) | EP1152763B1 (enExample) |
| JP (1) | JP2002537246A (enExample) |
| KR (1) | KR20010102239A (enExample) |
| AT (1) | ATE228843T1 (enExample) |
| AU (1) | AU3278800A (enExample) |
| DE (2) | DE19906978B4 (enExample) |
| DK (1) | DK1152763T3 (enExample) |
| ES (1) | ES2188513T3 (enExample) |
| WO (1) | WO2000048582A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119863A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen |
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| DE10163667B4 (de) * | 2001-12-21 | 2006-10-26 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression |
| DE10304141B4 (de) | 2003-02-03 | 2006-03-09 | Hf Arzneimittelforschung Gmbh | Verfahren zur Herstellung von Chinazolin-Alkaloiden |
| DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
| DE10354893B4 (de) * | 2003-11-24 | 2011-03-10 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen |
| RU2460515C1 (ru) * | 2011-10-17 | 2012-09-10 | Тагир Рафаилович Гизатуллин | Способ дезинтоксикационно-инфузионного лечения больных при употреблении дезоморфина |
| KR102728780B1 (ko) * | 2021-11-30 | 2024-11-08 | 이화여자대학교 산학협력단 | 데옥시바시시논을 유효성분으로 포함하는 미백용 조성물 및 상기 데옥시바시시논 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU605614A1 (ru) * | 1971-10-20 | 1978-05-05 | Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср | Антихолинэстеразное средство |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| US5591738A (en) * | 1994-10-14 | 1997-01-07 | Nda International, Inc. | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof |
| DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
-
1999
- 1999-02-19 DE DE19906978A patent/DE19906978B4/de not_active Expired - Fee Related
-
2000
- 2000-02-08 AU AU32788/00A patent/AU3278800A/en not_active Abandoned
- 2000-02-08 JP JP2000599374A patent/JP2002537246A/ja not_active Abandoned
- 2000-02-08 ES ES00910649T patent/ES2188513T3/es not_active Expired - Lifetime
- 2000-02-08 DK DK00910649T patent/DK1152763T3/da active
- 2000-02-08 EP EP00910649A patent/EP1152763B1/de not_active Expired - Lifetime
- 2000-02-08 WO PCT/EP2000/000974 patent/WO2000048582A2/de not_active Ceased
- 2000-02-08 AT AT00910649T patent/ATE228843T1/de not_active IP Right Cessation
- 2000-02-08 US US09/889,648 patent/US6599511B1/en not_active Expired - Fee Related
- 2000-02-08 DE DE50000864T patent/DE50000864D1/de not_active Expired - Fee Related
- 2000-02-08 KR KR1020017010490A patent/KR20010102239A/ko not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| Chem. Abstr. 100:132532 t * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010102239A (ko) | 2001-11-15 |
| AU3278800A (en) | 2000-09-04 |
| DE50000864D1 (de) | 2003-01-16 |
| ES2188513T3 (es) | 2003-07-01 |
| DE19906978A1 (de) | 2000-08-24 |
| ATE228843T1 (de) | 2002-12-15 |
| JP2002537246A (ja) | 2002-11-05 |
| WO2000048582A3 (de) | 2001-04-12 |
| EP1152763B1 (de) | 2002-12-04 |
| US6599511B1 (en) | 2003-07-29 |
| WO2000048582A2 (de) | 2000-08-24 |
| DK1152763T3 (da) | 2003-03-24 |
| EP1152763A2 (de) | 2001-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004007888T2 (de) | Transdermal granisetron | |
| DE3528979C2 (enExample) | ||
| EP0655916B1 (de) | Mittel zur transdermalen applikation enthaltend 3-keto-desogestrel | |
| DE69117505T2 (de) | Polyisobutylenklebstoffe für transdermische vorrichtungen | |
| DE69916492T3 (de) | Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen | |
| DE4301782C1 (de) | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit | |
| DE60311449T2 (de) | Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE19906978B4 (de) | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit | |
| DE69614419T2 (de) | Transdermale Formulierung eines Mittels muscarinischer Wirkung | |
| DE4343838C2 (de) | Deuteriertes Arzneimittel in transdermaler Applikation und Verfahren zu seiner Herstellung | |
| DE19957234A1 (de) | Pharmazeutisches Pflaster enthaltend ätherische Öle | |
| DE19906975B4 (de) | Arzneiform zur Behandlung von Alzheimer'scher Demenz | |
| EP1154776A1 (de) | Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus | |
| DE69322201T2 (de) | Selbstklebendes Matrixsystem für die transdermal-gesteuerte Abgabe von Piribedil | |
| DE10163421A1 (de) | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum | |
| EP1383503B1 (de) | Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen | |
| DE60024408T2 (de) | Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen | |
| EP0669826A1 (de) | (-)-metrifonat enthaltendes arzneimittel | |
| EP1235580A2 (de) | Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne | |
| DE2532180C2 (de) | Verwendung von Etozolin bei der Bekämpfung der Hypertonie | |
| DE3430389A1 (de) | Arzneimittel fuer die gewichtsreduktion | |
| WO2008064815A2 (de) | Zubereitung zur transdermalen verabreichung von galanthamin | |
| DE10162704A1 (de) | Verwendung von Buprenorphin zur Therapie der Harninkontinenz | |
| DE10157745A1 (de) | Transdermales therapeutisches System zur Verabreichung von 17alpha-Estradiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, 56626 ANDERNACH, |
|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HF ARZNEIMITTELFORSCHUNG GMBH, 59368 WERNE, DE |
|
| 8339 | Ceased/non-payment of the annual fee |